沙格列汀联合阿卡波糖治疗初诊老年2型糖尿病的疗效

Efficacy of saxagliptin combined with acarbose in the treatment of newly diagnosed type 2 diabetes mellitus

目的探讨和分析沙格列汀联合阿卡波糖治疗初诊老年2型糖尿病的临床治疗效果。方法将本院2015年1月~2017年1月期间收治的60例初诊老年2型糖尿病患者选取为本次的研究对象,将其按照随机数字表法分为对照组与研究组,每组30例。对照组患者采用阿卡波糖进行治疗,研究组患者采用沙格列汀联合阿卡波糖进行治疗,治疗时间为3个月,将2组患者在分别进行不同方法治疗之后的糖化血红蛋白、低血糖发生率、体质量指数变化以及血糖水平的变化进行观察和对比。结果对照组患者的低血糖发生率为23.33%,研究组患者的低血糖发生率为6.67%,研究组患者的低血糖发生率明显的低于对照组,2组间差异具有统计学意义（P〈0.05）;研究组患者的糖化血红蛋白水平明显的低于对照组患者,2组相比差异具有统计学意义（P〈0.05）;研究组患者的总治疗费用与对照组相比差异不具有统计学意义。结论沙格列汀联合阿卡波糖治疗初诊老年2型糖尿病的临床治疗效果比较显著,能够使患者的血糖水平得到明显的降低,具有很高的安全性,低血糖发生率也明显降低,同时还可以减少患者的体重影响,治疗过程中的总费用也没有增加,不会对患者造成经济负担。

Objective To investigate the clinical effect and analysis of Shah Glenn Dean combined with acarbose in the treatment of newly diagnosed elderly patients with type 2 diabetes mellitus. Methods 60 cases of newly diagnosed elderly patients treated in our hospital during the period from January 2015 to January 2017 in patients with type 2 diabetes mellitus is selected as the object of this study,they were randomly divided into control group and study group,30 cases in each group. The control group was treated with acarbose treatment,the study group was treated with Shah Glenn Dean combined acarbose treatment,treatment time was 3months,glycosylated hemoglobin,after two groups of patients were in different treatment of hypoglycemia were observed and compared the rate of change,body mass index and blood glucose level changes. Results The patients in the control group,the incidence of hypoglycemia was 23. 33%,patients in the study group,the incidence of hypoglycemia was 6. 67%,patients in the study group,the incidence of hypoglycemia was significantly lower than that of control group,the difference was statistically significant between the groups（ P 〈0. 05）; glycosylated hemoglobin levels in the study group were significantly lower than that of the control group of two patients,the difference was statistically significant between the groups（ P〈 0. 05）; the total cost of the patients in the treatment group compared with the control group had no significant difference,the difference was not statistically significant. Conclusion Significant clinical therapeutic effect of saxagliptin combined with acarbose in the treatment of newly diagnosed elderly patients with type 2 diabetes,can make the patient＇s blood glucose levels were significantly lower,with high security,the incidence of hypoglycemia was significantly reduced,but also can reduce the weight of patients,the total cost in the course of treatment did not increase that will not cause economic burden on patients,it is worthy of clinical application.